Overview
ANNX market data
Price History
ANNX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.33 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.28 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.03 – $7.18 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $856.1M · P/B 3.43.
Company News
Citizens Upgrades Annexon to Market PerformBenzinga · Aug 13, 2026, 1:48 PM
8-K filing — Annexon, Inc. (ANNX)SEC EDGAR · Aug 12, 2026, 10:30 AM
Annexon Q2 EPS $(0.28) Misses $(0.24) EstimateBenzinga · Aug 12, 2026, 10:14 AM
Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic AtrophyBenzinga · Aug 12, 2026, 10:03 AM
Annexon Reports Early Strength Improvement And Clinically Meaningful Disability Reduction With Tanruprubart In First Ten US And European Guillain-Barré Syndrome Patients From Ongoing FORWARD StudyBenzinga · Aug 6, 2026, 12:17 PM
Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford FinanceBenzinga · Jul 31, 2026, 1:27 PM
Citizens Initiates Coverage On Annexon with Market Underperform Rating, Announces Price Target of $3Benzinga · Jul 21, 2026, 12:34 PM
Annexon shares are trading higher after the company announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists. Also, Needham maintained a Buy rating on the stock and raised its price target from $11 to $25.Benzinga · Jul 15, 2026, 11:40 AM
Needham Maintains Buy on Annexon, Raises Price Target to $25Benzinga · Jul 15, 2026, 11:35 AM
Annexon Presents Data On Neuroprotective Effect Of Vonaprument At American Society Of Retina Specialists 44th Annual Scientific MeetingBenzinga · Jul 14, 2026, 8:06 PM